John Fowler is our Co-Founder and has served as our Chief Executive Officer since March 2015 and as a member of our board of directors since February 2015. Prior to founding our company, Mr. Fowler was the Chief Executive Officer of HealthCPA, a provider of patient advocacy and insurance navigation services, from June 2009 to October 2014. Mr. Fowler received his Bachelor of Arts and Master of Business Administration degrees from Stanford University.
Christopher Kirk, Ph.D
President and CSO, Co-Founder
Christopher Kirk, Ph.D., is our Co-Founder and has served as our President and Chief Scientific Officer since March 2015 and as a member of our board of directors since February 2015. Before founding our company, Dr. Kirk was the Vice President of research at Onyx Pharmaceuticals, Inc., or Onyx, from April 2010 to April 2014. Dr. Kirk previously served as Director of Pharmacology and biology at Onyx and at Proteolix, Inc. Dr. Kirk has served as a member of the scientific advisory board at Karyopharm Therapeutics, Inc., C4 Therapeutics, Inc., and Avidity Biosciences LLC.
Dr. Kirk received his Bachelor of Science in Biochemistry from the University of California, Davis, and his Doctor of Philosophy in Cellular and Molecular Biology from the University of Michigan.
Noreen R. Henig, M.D.
Chief Medical Officer
Noreen Roth Henig, M.D. is an accomplished leader whose career spans clinical practice, academic medicine, translational science, clinical development, medical and regulatory affairs. She currently serves on the Board of Avidity Biosciences and most recently served as Chief Medical Officer of Breath Therapeutics, which was acquired by Zambon SpA in 2019. As CMO, Dr. Henig built and led the clinical team and was responsible for all development activities including clinical and non-clinical science, clinical operations, regulatory, project management, and medical affairs. Prior to joining Breath, Dr. Henig was Chief Medical Officer at ProQR Therapeutics where she brought two unique RNA oligonucleotides through early clinical trials in rare diseases. Before ProQR, Dr. Henig spent 2008 through 2014 at Gilead Sciences where she held roles with increasing responsibility, including building and leading a global medical affairs organization, strategic development of clinical trials Phase 2-4, regulatory strategy, corporate development, leadership of key alliances and commercial strategy. Prior to joining industry, Dr. Henig spent nearly 10 years in leadership roles within academic medicine at Stanford University and California Pacific Medical Center. She is a board-certified physician in Pulmonary, Critical Care and board eligible in Allergy and Immunology. Dr. Henig received her B.A. from Yale University and her M.D. from Albert Einstein College of Medicine of Yeshiva University in 1991 with a distinction in immunology. She trained in Internal Medicine at University of California, San Francisco and in Pulmonary/Critical Care and Allergy/Immunology at University of Washington, Seattle.
Marc L. Belsky
Chief Financial Officer
Marc L. Belsky has served as our Chief Financial Officer and secretary since April 2018. Prior to joining us, from October 2009 to April 2018, Mr. Belsky held several roles at Five Prime Therapeutics, Inc., a publicly held biopharmaceutical company, including most recently as Senior Vice President and Chief Financial Officer. Before that, Mr. Belsky served in various roles at Cell Genesys, Inc., a biotechnology company acquired by BioSante Pharmaceuticals, Inc., Active Aero Group, Inc., DataWave Systems Inc., and Michigan National Corporation, a holding company for Michigan National Bank, which was acquired by BANA Holding Corporation. Mr. Belsky started his career as an auditor with Coopers & Lybrand.
Mr. Belsky received a Bachelor of Science degree in accounting from Wayne State University and a Master of Business Administration degree from the University of Michigan. He is also a certified public accountant.
Senior Vice President of Strategy and External Affairs
Celia Economides has nearly 20 years of experience in the life sciences and biotech industries, spanning finance, corporate strategy, communications, patient advocacy, clinical, medical and government affairs. Before joining Kezar, Ms. Economides served as Vice President, corporate affairs at Aurinia Pharmaceuticals, Inc, where she led the company’s investor relations, corporate communications, and patient advocacy efforts, establishing relationships and alliances with key advocacy groups across the company’s therapeutic focus. Previously, Ms. Economides served as Director, Global Medical Affairs and Director, Clinical Operations at BioMarin Pharmaceutical, Inc. after the Company’s acquisition of Prosensa where she led IR and corporate communications. Earlier in her career, she led investor relations and program development at the Biotechnology Innovation Organization (BIO) and worked at a healthcare-focused hedge fund and in financial services focusing on the biotech sector. Ms. Economides currently serves on the board of directors of Altum Pharmaceuticals Inc, a private company focused on women’s health. She received her Master of Public Health from Columbia University and a Bachelor of Arts from McGill University.